Diverse molecular targets for therapeutic strategies in alzheimer's disease

Journal of Korean Medical Science

Volumn 29, Issue 7, 2014, Pages 893-902

  Han, Sun Ho ^a   Mook Jung, Inhee ^a  

^a Seoul National University   (South Korea)

Author keywords

Aggregation; Alzheimer disease; Amyloid beta peptides; Glucose metabolism; Immunotherapy; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY; N METHYLASPARTIC ACID; TAU PROTEIN;

ALZHEIMER DISEASE; ANTAGONISTS AND INHIBITORS; BRAIN; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; BRAIN; HUMANS; IMMUNOTHERAPY; N-METHYLASPARTATE; TAU PROTEINS;

EID: 84919882105     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.7.893     Document Type: Review

References (125)

1. Thies W, Bleiler L; Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013; 9: 208-45.
2. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of demen-tia: estimates for 2009. Alzheimers Dement 2010; 6: 98-103.
3. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hy-pothesis. Science 1992; 256: 184-5.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: prog-ress and problems on the road to therapeutics. Science 2002; 297: 353-6.
5. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeu-tics. Nat Rev Drug Discov 2011; 10: 698-712.
6. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspar-tic protease BACE. Science 1999; 286: 735-41.
7. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999; 398: 513-7.
8. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, An-naert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387-90.
9. Mucke L. Neuroscience: Alzheimer's disease. Nature 2009; 461: 895-7.
10. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synap-tic plasticity and memory. Nat Med 2008; 14: 837-42.
11. Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol 1998; 8: 425-7.
12. Geschwind DH. Tau phosphorylation, tangles, and neurodegenera-tion: the chicken or the egg? Neuron 2003; 40: 457-60.
13. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491-5.
14. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, et al. Enhanced neurofibrillary degenera-tion in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-91.
15. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, et al. Dendritic function of tau me-diates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-97.
16. Buckholtz NS. Perspective: in search of biomarkers. Nature 2011; 475: S8.
17. Callaway E. Alzheimer's drugs take a new tack. Nature 2012; 489: 13-4.
18. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month exten-sion: the Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-8.
19. Van Dyck CH, Tariot PN, Meyers B, Malca Resnick E; Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Al-zheimer Dis Assoc Disord 2007; 21: 136-43.
20. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Ger-gel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.
21. Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm AL, Jansson-Blixt C, Haglund A; Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-65.
22. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Al-zheimer Dis Assoc Disord 2008; 22: 209-21.
23. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7.
24. Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009; 7: 167-85.
25. Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, Mondadori CG, Pearlman R. SGS742: the first GABA(B) receptor an-tagonist in clinical trials. Biochem Pharmacol 2004; 68: 1479-87.
26. Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother 2010; 10: 711-28.
27. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) 1999; 142: 334-42.
28. Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010; 13: 1021-33.
29. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, et al. Ginkgo bi-loba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300: 2253-62.
30. Park SJ, Jung HJ, Son MS, Jung JM, Kim DH, Jung IH, Cho YB, Lee EH, Ryu JH. Neuroprotective effects of INM-176 against lipopolysaccharide-induced neuronal injury. Pharmacol Biochem Behav 2012; 101: 427-33.
31. Shi C, Zhao L, Zhu B, Li Q, Yew DT, Yao Z, Xu J. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem Biol Interact 2009; 181: 115-23.
32. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheim-er's disease. Nat Rev Neurosci 2007; 8: 499-509.
33. Ghosh AK, Gemma S, Tang J. Beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 2008; 5: 399-408.
34. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, Hong L, Loy JA, Nguyen C, Koelsch G, et al. Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 2001; 44: 2865-8.
35. Ghosh AK, Brindisi M, Tang J. Developing β-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 2012; 120: 71-83.
36. Sisodia SS, St George-Hyslop PH. Gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 2002; 3: 281-90.
37. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat Rev Neurosci 2006; 7: 93-102.
38. Henley DB, May PC, Dean RA, Siemers ER. Development of semagace-stat (LY450139), a functional gamma-secretase inhibitor, for the treat-ment of Alzheimer's disease. Expert Opin Pharmacother 2009; 10: 1657-64.
39. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neu-rochem 2007; 101: 1172-84.
40. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2008; 283: 29639-43.
41. Nakagami Y, Nishimura S, Murasugi T, Kaneko I, Meguro M, Marumo-to S, Kogen H, Koyama K, Oda T. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 2002; 137: 676-82.
42. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and re-duces amyloid in vivo. J Biol Chem 2005; 280: 5892-901.
43. McKoy AF, Chen J, Schupbach T, Hecht MH. A novel inhibitor of amy-loid β (Aβ) peptide aggregation: from high throughput screening to effi-cacy in an animal model of Alzheimer disease. J Biol Chem 2012; 287: 38992-9000.
44. Bush AI. Drug development based on the metals hypothesis of Alzheim-er's disease. J Alzheimers Dis 2008; 15: 223-40.
45. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harri-son J, Lannfelt L, Blennow K, Zetterberg H, et al. PBT2 rapidly im-proves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimers Dis 2010; 20: 509-16.
46. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is as-sociated with decreased interstitial Abeta. Neuron 2008; 59: 43-55.
47. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Sel-koe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amy-loid plaque formation. Neurobiol Dis 1996; 3: 16-32.
48. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 1996; 215: 173-6.
49. Kuo YM, Emmerling MR, Woods AS, Cotter RJ, Roher AE. Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 1997; 237: 188-91.
50. Schilling S, Appl T, Hoffmann T, Cynis H, Schulz K, Jagla W, Friedrich D, Wermann M, Buchholz M, Heiser U, et al. Inhibition of glutaminyl cy-clase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. J Neurochem 2008; 106: 1225-36.
51. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU. Gluta-minyl cyclases unfold glutamyl cyclase activity under mild acid condi-tions. FEBS Lett 2004; 563: 191-6.
52. Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neu-rosci 2006; 24: 167-76.
53. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 2012; 2012: 756357.
54. Weninger SC, Yankner BA. Inflammation and Alzheimer disease: the good, the bad, and the ugly. Nat Med 2001; 7: 527-8.
55. Lambert JC, Grenier-Boley B, Chouraki V, Heath S, Zelenika D, Fievet N, Hannequin D, Pasquier F, Hanon O, Brice A, et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis 2010; 20: 1107-18.
56. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70: 1672-7.
57. Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheim-er's disease or mild cognitive impairment? Front Aging Neurosci 2010; 2. pii: 19.
58. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008; 70: 17-24.
59. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Good-man SN. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23: 159-69.
60. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's dis-ease. Neurology 1999; 53: 197-201.
61. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC; Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, con-trolled study. Neurology 2004; 62: 66-71.
62. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23: 8-21.
63. De Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, Kremer B. No effect of one-year treatment with indometha-cin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 2008; 3: e1475.
64. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Al-zheimer disease: a randomized controlled trial. JAMA 2009; 302: 2557-64.
65. Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, Zanetti O, Rossini PM. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res 2009; 21: 102-10.
66. Delrieu J, Ousset PJ, Caillaud C, Vellas B. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 2012; 120: 186-93.
67. Fu HJ, Liu B, Frost JL, Lemere CA. Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 2010; 9: 197-206.
68. Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A. Immunotherapy for Alzheimer's dis-ease: from anti-β-amyloid to tau-based immunization strategies. Im-munotherapy 2012; 4: 213-38.
69. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
70. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 2003; 23: 8532-8.
71. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101.
72. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Al-zheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 8850-5.
73. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-7.
74. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al. Subacute meningoen-cephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54.
75. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al. Long-term effects of Abe-ta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-23.
76. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Ger-stein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amy-loid beta-induced deficits in an Alzheimer's disease mouse model. Sci-ence 2007; 316: 750-4.
77. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Gui-maraes A, DeTure M, Ramsden M, McGowan E, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Sci-ence 2005; 309: 476-81.
78. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immuno-therapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-32.
79. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 2001; 168: 402-12.
80. Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White CL 3rd. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 2004; 63: 287-301.
81. Schneider A, Mandelkow E. Tau-based treatment strategies in neuro-degenerative diseases. Neurotherapeutics 2008; 5: 443-57.
82. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009; 70: 922-31.
83. Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheim-er's disease? J Clin Psychiatry 2009; 70: 919-21.
84. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X, et al. Caffeine reverses cogni-tive impairment and decreases brain amyloid-beta levels in aged Al-zheimer's disease mice. J Alzheimers Dis 2009; 17: 661-80.
85. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degenera-tion in vivo. Proc Natl Acad Sci U S A 2005; 102: 6990-5.
86. Domínguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem 2012; 287: 893-904.
87. Eldar-Finkelman H, Martinez A. GSK-3 inhibitors: preclinical and clin-ical focus on CNS. Front Mol Neurosci 2011; 4: 32.
88. Del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, Vericat JA, Redondo P, Fleet D, León T. Treatment of Al-zheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J Al-zheimers Dis 2013; 33: 205-15.
89. Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 2014; 88: 529-39.
90. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vi-tro and in cells. J Biol Chem 2005; 280: 3628-35.
91. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 2005; 280: 7614-23.
92. Crowe A, Huang W, Ballatore C, Johnson RL, Hogan AM, Huang R, Wichterman J, McCoy J, Huryn D, Auld DS, et al. Identification of ami-nothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 2009; 48: 7732-45.
93. Blass JP. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 2001; 66: 851-6.
94. Blass JP, Gibson GE, Hoyer S. The role of the metabolic lesion in Al-zheimer's disease. J Alzheimers Dis 2002; 4: 225-32.
95. Hoyer S. Brain glucose and energy metabolism abnormalities in spo-radic Alzheimer disease: causes and consequences: an update. Exp Gerontol 2000; 35: 1363-72.
96. Kurochkin IV, Goto S. Alzheimer's beta-amyloid peptide specifically in-teracts with and is degraded by insulin degrading enzyme. FEBS Lett 1994; 345: 33-7.
97. McDermott JR, Gibson AM. Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-de-grading enzyme. Neurochem Res 1997; 22: 49-56.
98. Sudoh S, Frosch MP, Wolf BA. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 2002; 41: 1091-9.
99. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading en-zyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003; 100: 4162-7.
100. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000; 20: 1657-65.
101. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implica-tions of insulin resistance and glucose metabolism in Alzheimer's dis-ease pathogenesis. J Cell Mol Med 2011; 15: 1807-21.
102. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, Mook-Jung I. Accu-mulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy 2012; 8: 1842-4.
103. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011; 60: 910-20.
104. Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, Wolfe CL, Wheeler JS, Coulter KR, Kilkuskie PM, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT): relationship to newly identified mitochondrial py-ruvate carrier proteins. PLoS One 2013; 8: e61551.
105. Divakaruni AS, Wiley SE, Rogers GW, Andreyev AY, Petrosyan S, Lovis-cach M, Wall EA, Yadava N, Heuck AP, Ferrick DA, et al. Thiazolidine-diones are acute, specific inhibitors of the mitochondrial pyruvate car-rier. Proc Natl Acad Sci U S A 2013; 110: 5422-7.
106. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, et al. Mitochondrial ab-normalities in Alzheimer's disease. J Neurosci 2001; 21: 3017-23.
107. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006; 15: 1437-49.
108. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 2005; 19: 2040-1.
109. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A 2010; 107: 18670-5.
110. Cha MY, Han SH, Son SM, Hong HS, Choi YJ, Byun J, Mook-Jung I. Mi-tochondria-specific accumulation of amyloid β induces mitochondrial dysfunction leading to apoptotic cell death. PLoS One 2012; 7: e34929.
111. Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, Oliveira CR, Moreira PI. Insulin signaling, glucose metabolism and mi-tochondria: major players in Alzheimer's disease and diabetes interre-lation. Brain Res 2012; 1441: 64-78.
112. Valla J, Schneider L, Niedzielko T, Coon KD, Caselli R, Sabbagh MN, Ahern GL, Baxter L, Alexander G, Walker DG, et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive im-pairment. Mitochondrion 2006; 6: 323-30.
113. Parihar MS, Brewer GJ. Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 2007; 292: C8-23.
114. Swerdlow RH. Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta 2011; 1812: 1630-9.
115. Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect 2010; 23: 518-23.
116. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from ba-sic science to novel clinical applications to CNS disorders. Drugs 2010; 70: 287-312.
117. Leuner K, Kurz C, Guidetti G, Orgogozo JM, Müller WE. Improved mi-tochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam. Front Neurosci 2010; 4. pii: 44.
118. Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH. Impaired mi-tochondrial biogenesis, defective axonal transport of mitochondria, ab-normal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 2011; 20: 4515-29.
119. Chen S, Owens GC, Makarenkova H, Edelman DB. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 2010; 5: e10848.
120. Kim C, Choi H, Jung ES, Lee W, Oh S, Jeon NL, Mook-Jung I. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 2012; 7: e42983.
121. Kim C, Nam DW, Park SY, Song H, Hong HS, Boo JH, Jung ES, Kim Y, Baek JY, Kim KS, et al. O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment. Neuro-biol Aging 2013; 34: 275-85.
122. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006; 9: 13-33.
123. Tallent MK, Varghis N, Skorobogatko Y, Hernandez-Cuebas L, Whelan K, Vocadlo DJ, Vosseller K. In vivo modulation of O-GlcNAc levels regu-lates hippocampal synaptic plasticity through interplay with phos-phorylation. J Biol Chem 2009; 284: 174-81.
124. Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, He Y, Whit-worth GE, Stubbs KA, McEachern EJ, Davies GJ. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 2008; 4: 483-90.
125. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, et al. Amyloid β deposi-tion, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67.